Has the French Biotech Industry valuation changed over the past few years?

Investors are optimistic on the French Biotechs industry, and appear confident in long term growth rates. The 3-year average PS ratio of 7.2x is lower than the industry's current PS ratio of 19.3x.

Which industries have driven the changes within the French Healthcare industry?

There are no additional sub-industries under this industry.

French (CAC) Biotech Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Thu, 18 Jun 2026	€9.6b	€495.6m	-€861,898,613.71	17.5x	-11.1x	19.3x
Sat, 16 May 2026	€10.9b	€494.3m	-€859,457,093.42	16x	-12.6x	22x
Mon, 13 Apr 2026	€11.4b	€502.3m	-€816,714,237.95	16.6x	-13.9x	22.6x
Wed, 11 Mar 2026	€11.4b	€560.8m	-€765,552,385.25	12.6x	-14.9x	20.3x
Fri, 06 Feb 2026	€10.8b	€559.5m	-€763,167,218.00	13.8x	-14.1x	19.3x
Sun, 04 Jan 2026	€11.8b	€641.7m	-€694,191,096.75	9.9x	-17x	18.4x
Tue, 02 Dec 2025	€2.5b	€637.0m	-€431,041,731.13	10.6x	-5.9x	4x
Thu, 30 Oct 2025	€2.5b	€637.7m	-€418,669,015.70	10.1x	-5.9x	3.8x
Sat, 27 Sep 2025	€2.3b	€643.6m	-€455,630,522.89	16x	-5x	3.6x
Mon, 25 Aug 2025	€2.7b	€673.7m	-€444,936,702.73	15.5x	-6x	3.9x
Wed, 23 Jul 2025	€1.9b	€655.6m	-€451,640,083.19	15x	-4.2x	2.9x
Fri, 20 Jun 2025	€1.9b	€667.1m	-€496,591,720.80	17.5x	-3.9x	2.9x
Sun, 18 May 2025	€2.4b	€671.9m	-€679,275,078.11	39.5x	-3.5x	3.6x
Tue, 15 Apr 2025	€2.2b	€650.8m	-€549,229,167.55	14.1x	-4.1x	3.4x
Thu, 13 Mar 2025	€2.3b	€651.7m	-€520,359,851.81	16.6x	-4.5x	3.6x
Sat, 08 Feb 2025	€2.4b	€650.4m	-€528,002,583.50	16.3x	-4.6x	3.7x
Mon, 06 Jan 2025	€2.4b	€650.7m	-€528,615,557.34	18.5x	-4.5x	3.7x
Wed, 04 Dec 2024	€2.4b	€654.3m	-€548,189,251.43	18.1x	-4.3x	3.6x
Fri, 01 Nov 2024	€2.8b	€640.9m	-€517,986,963.58	18.8x	-5.4x	4.4x
Sun, 29 Sep 2024	€2.9b	€640.6m	-€509,140,447.82	19.6x	-5.6x	4.5x
Tue, 27 Aug 2024	€3.1b	€520.2m	-€578,934,243.44	37.2x	-5.4x	6x
Thu, 25 Jul 2024	€2.9b	€511.8m	-€567,032,346.37	29.2x	-5.1x	5.7x
Sat, 22 Jun 2024	€3.0b	€514.4m	-€569,641,165.19	26.4x	-5.2x	5.8x
Mon, 20 May 2024	€3.3b	€502.3m	-€592,424,218.48	27.9x	-5.6x	6.6x
Wed, 17 Apr 2024	€3.3b	€515.7m	-€629,721,423.09	27.6x	-5.2x	6.3x
Fri, 15 Mar 2024	€3.1b	€567.9m	-€645,961,276.84	21.4x	-4.8x	5.4x
Sun, 11 Feb 2024	€3.0b	€558.9m	-€674,772,026.21	22.1x	-4.4x	5.4x
Tue, 09 Jan 2024	€3.2b	€594.2m	-€682,901,948.00	23.5x	-4.7x	5.4x
Thu, 07 Dec 2023	€3.2b	€594.7m	-€685,625,024.00	22x	-4.7x	5.4x
Sat, 04 Nov 2023	€3.3b	€803.3m	-€564,210,227.00	21.2x	-5.9x	4.1x
Mon, 02 Oct 2023	€3.6b	€850.1m	-€630,409,790.00	14.2x	-5.6x	4.2x
Wed, 30 Aug 2023	€3.8b	€818.0m	-€726,469,920.00	24.1x	-5.2x	4.6x
Fri, 28 Jul 2023	€3.8b	€817.8m	-€735,672,254.00	24.4x	-5.2x	4.7x
Sun, 25 Jun 2023	€3.9b	€820.0m	-€744,113,037.00	25.4x	-5.2x	4.7x


FR Market	2.89%
Healthcare	-1.49%
Biotech	3.90%
Biotech	3.90%

Company	Last Price	7D	1Y	Valuation
ABVX ABIVAX Société Anonyme	€86.20	1.2% +€83.7m	1,526.4%	PS1396.3x
GNFT Genfit	€10.38	17.7% +€77.7m	199.7%	PS7.9x
NANO Nanobiotix	€30.40	4.8% +€71.0m	675.5%	PS47.3x
VLA Valneva	€2.29	3.4% +€14.2m	-3.0%	PS2.8x
ALVIO Valerio Therapeutics Société anonyme	€0.21	5.8% +€5.7m	216.7%	PS40.6x

Announcement • Jun 11

Sensorion Achieves Key Regulatory Milestones for Sens-601 for Gjb2-Related Hearing Loss and Selects Program as Lead Gene Therapy Candidate

Sensorion has selected SENS-601 which addresses GJB2-related hearing loss as its lead program. A Clinical trial application has been filed in Canada and France to evaluate the safety, tolerability and efficacy of intra-cochlear administration of SENS-601, for the treatment of GJB2 gene-mediated hearing loss in paediatric patients. Sensorion has recently submitted Clinical Trial Applications for SENS-601 (Hearconnex) in Canada, and in France, with Fast Track procedure granted by the French Agency (ANSM). The trial is intended to evaluate the safety, tolerability and efficacy of intra-cochlear administration of SENS-601, for the treatment of GJB2 gene-mediated hearing loss in pediatric patients. Hearconnex will also assess the clinical safety, performance and ease-of-use of the delivery system developed by Sensorion. The submissions follow productive pre-submission alignment discussions with the regulatory authorities, and the Company has high confidence in the completeness and scientific quality of the dossier. The Fast Track procedure granted in France provides a significantly reduced assessment period compared to the standard pathway. The IND submission with the FDA in the U.S. and the submission in Australia are on track by year-end 2026. Sensorion has decided to discontinue the clinical development activity for SENS-501 for OTOF-related hearing loss after conducting a strategic review of its therapeutic candidate pipeline and is consequently ending recruitment in the Audiogene trial. OTOF-related hearing loss is an ultra-rare condition, and the recent availability of a gene therapy demonstrating meaningful clinical efficacy in this indication has notably changed the development environment for SENS-501. In this context, the Board and management concluded that concentrating Sensorion’s resources on SENS-601, where the unmet need is an order of magnitude larger and no approved therapy is currently available, is the right strategic decision for the Company and its stakeholders. Sensorion extends gratitude to the clinical teams, investigators, and patients of the Audiogene trial for their contribution to advancing gene therapy for hearing loss. The scientific and operational platform built through this work, developed in close collaboration with Prof. Christine Petit’s team (Institut reConnect, Institut de l’Audition, Institut Pasteur, Inserm, CNRS), are directly transferrable to SENS-601 and provide a unique and foundational head start for the program. In accordance with applicable regulatory requirements, Sensorion remains fully committed to ensuring the long-term follow-up of all patients enrolled in the Audiogene trial. The cash runway is extended until the end of 2027, supporting the execution of the clinical advancement of SENS-601 and the generation of first in human data. SENS-601 (GJB2-GT) is an innovative AAV-based gene therapy program developed in collaboration with Prof. Christine Petit's team (Institut reConnect, Institut de l'Audition, Institut Pasteur, Inserm, CNRS) to treat hearing loss linked to mutations in the GJB2 gene, which plays a critical role in maintaining the ionic balance necessary for sound transduction in the inner ear. GJB2 mutations represent the most common cause of genetic congenital deafness, responsible for approximately 50% of autosomal recessive non-syndromic hearing loss. Recent research has also established that GJB2 mutations are found in early onset forms of severe presbycusis in adults, which appear to be monogenic potentially treatable by gene therapy. As such, SENS-601 has the potential to address three distinct pathologies: paediatric congenital deafness, progressive forms of hearing loss in children, and early onset of presbycusis in adults. With no approved gene therapy currently available for GJB2-related hearing loss, SENS-601 has the potential to be among the first gene therapy addressing GJB2 mutations. This program is partially funded by the French State as part of the France 2030 investment plan (ConnexGene project, with Bpifrance). SENS-501 (OTOF-GT) is an innovative gene therapy program developed to treat a specific form of congenital deafness linked to mutations in the OTOF (otoferlin) gene. This gene plays a key role in the transmission of auditory signals between the hair cells of the inner ear and the auditory nerve. When this gene is defective, affected individuals are born with severe to profound hearing loss. The aim of SENS-501 (OTOF-GT) is to restore hearing by introducing a functional copy of the OTOF gene directly into hair cells via viral vector technology (AAV). This therapy aims to restore the normal process of converting sound into electrical signals, enabling patients to regain their hearing ability. This gene therapy for patients suffering from otoferlin deficiency has been developed in the framework of RHU AUDINNOVE, a consortium composed of Sensorion with the Necker Enfants Malades Hospital, the Institut Pasteur, and the Fondation pour l’Audition. The project is partially financed by the French National Research Agency, through the “investing for the future” program (ref: ANR-18-RHUS-0007). The OTOF gene targeted by the Audiogene trial was discovered in 1999 at the Institut Pasteur, by Prof. Christine Petit's team (Institut reConnect, Institut de l'Audition, Institut Pasteur), who also unravelled the pathophysiology of the corresponding deafness (DFNB9).

Announcement • Jun 09

Genfit Launches Nashnext Test Powered by Nis4 Technology Via Labcorp Ondemand for Identification of At-Risk Mash

GENFIT announced that access to Labcorp’s NASHnext, a diagnostic test to identify at-risk MASH (Metabolic dysfunction-Associated SteatoHepatitis), powered by GENFIT’s proprietary non-invasive diagnostic technology NIS4, is now available through Labcorp OnDemand. Labcorp’s platform allows patients expanded access to certain diagnostic tests online, which a physician can approve and review without requiring an in-person doctor's visit. GENFIT’s non-invasive technology was specifically designed to identify patients with at-risk MASH and is able to power a test that can capture both disease activity and fibrotic burden even if still at F2 (stage 2 fibrosis), thus providing helpful information to support clinical evaluation, diagnosis, and treatment decisions. By enabling earlier and more accurate identification of at-risk patients, this approach helps address key diagnostic gaps across primary care, endocrinology, and broader clinical settings. Labcorp’s NASHnext is now available through Labcorp OnDemand, a digital interface for patients that provides them with an additional access channel to healthcare professionals within the routine care framework, with all testing requests reviewed by a healthcare professional. It is intended to broaden access to testing in the United States, in anticipation of a reimbursement decision by Medicare/Medicaid that would enable access across relevant patient populations. NASHnext testing could be useful to a U.S. patient population in the high tens of millions of individuals, reflecting the need to screen broadly to identify patients with at-risk MASH. This estimate is informed by the high and growing prevalence of metabolic risk factors in the U.S., including type 2 diabetes, obesity, or dyslipidemia, with a clear majority of adults presenting at least one such risk factor. Within this large population, a significant proportion already presents with elevated liver markers, and a subset may ultimately be eligible for treatment, with potential additional use in monitoring. NASHnext evaluates multiple blood-based markers associated with liver fat, inflammation, and liver fibrosis. Unlike routine liver enzyme tests alone, this approach looks at how several markers relate to each other. Results are intended to support clinical follow-up and monitoring decisions when interpreted by a healthcare provider and are only one part of a broader liver health evaluation. In practice, via the OnDemand platform, patients can order the test online, go to a patient service center for the blood draw, and see their test results rapidly on MyLabcorp app. With a high and growing prevalence of metabolic risk factors in the U.S., early detection of at-risk MASH could benefit a U.S. patient population in the high tens of millions of individuals, highlighting a significant unmet medical need. Liver biopsy currently remains the clinical standard for diagnosing at-risk MASH, but its use is highly constrained by its invasive and costly nature and difficult scalability. Labcorp’s NASHnext is a non-invasive diagnostic test to easily identify patients with at-risk MASH (Metabolic dysfunction-Associated SteatoHepatitis). It is powered by GENFIT’s proprietary non-invasive diagnostic technology NIS4. NIS4 and next-generation technology NIS2+ have been widely recognized over the past few years as showing a unique performance in identifying patients with at-risk MASH. This recognition is reflected through a growing body of scientific evidence (including publications in The Lancet and Nature Medicine), inclusion in joint guidelines from several international scientific societies (EASL-EASD-EASO), strong visibility within major consortia in the U.S. and Europe (NIMBLE and LITMUS), and its use in most large clinical trials conducted by key industry players in MASH. GENFIT is actively seeking to advance partnerships with pharmaceutical companies to support wider deployment of non-invasive testing for at-risk MASH and accelerate adoption in line with the expansion of MASH therapies. GENFIT is also exploring the development of an IVD-labeled (In Vitro Diagnostic) version of its non-invasive diagnostic technology, either independently or in collaboration with a diagnostic-focused partner, with the selected approach expected to reflect the most appropriate route to maximize long-term value for GENFIT.

French (CAC) Biotech Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Nicox Announces Positive Pre-Submission Regulatory Feedback in China Supporting NDA Filing for NCX 470

Valerio Therapeutics Société Anonyme Announces Board and Executive Changes

DBV Technologies Starts Infant Peanut Allergy Trial and Reports Positive Phase 3 Results

VLA: Future Travel Vaccines And Lyme Franchise Will Drive Reassessment

Consensus revenue estimates fall by 28%

Sensorion Achieves Key Regulatory Milestones for Sens-601 for Gjb2-Related Hearing Loss and Selects Program as Lead Gene Therapy Candidate

Cellectis S.A. Presents Final Phase 1 Results of Lasme-Cel and Preliminary Results on Eti-Cel At Eha 2026 Congress

Genfit Launches Nashnext Test Powered by Nis4 Technology Via Labcorp Ondemand for Identification of At-Risk Mash

TNG: Phase II Head And Neck Data Will Drive Future Repricing

Consensus EPS estimates fall by 13%

Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $119.999999 million.

IPH: 2026 Oncology Readouts Will Drive Reassessment Of Risk Reward Profile

Nanobiotix Raises US$100 Million in Oversubscribed Global Offering to Fund Oncology Programs

ABIONYX Pharma SA has filed a Follow-on Equity Offering in the amount of €18.699502 million.

Novacyt S.A., Annual General Meeting, Jun 30, 2026

GenSight Biologics S.A., Annual General Meeting, May 19, 2026